Neurocognitive impairment across the bipolar spectrum
- PMID: 22128808
- PMCID: PMC6493522
- DOI: 10.1111/j.1755-5949.2011.00262.x
Neurocognitive impairment across the bipolar spectrum
Abstract
Bipolar disorder is a severe mental illness that affects nearly 4.4% of the general population when bipolar spectrum disorders are taken into account. Neurocognitive impairment is thought to be a core deficit of this illness since it is present during euthymia. In fact, 40-60% of euthymic patients present with neurocognitive disturbances. Not only the clinical factors but also disturbances in neurocognition can influence the functional outcome of BD patients. Hence, further research is needed in order to clarify the relationship between these variables. Despite the growing body of evidence that has emerged during the last decade, no unique neurocognitive profile has been proposed yet for either BD subtype. The majority of the studies recluted heterogeneous samples (including both bipolar I and II) or focused on BD-I patients only. The aim of this review is to give an overall picture of the main neurocognitive disturbances found in the bipolar spectrum and particularly in BD-II, where the findings are more ambiguous. An extensive review of all the literature has been done regarding this subtype (from 1980 until July 2009). Data available until now suggest that deficits are present across the bipolar spectrum (BD-I and BD-II), but they seem slightly more severe in BD-I. The extent to which either subtype share-or not-some similarities is still unknown. More studies are required but it would also be interesting to reach a consensus in the neuropsychological assessment of BD to facilitate comparisons between the different studies.
© 2011 Blackwell Publishing Ltd.
Conflict of interest statement
Professor Eduard Vieta has served as consultant, advisor or speaker for the following companies: Almirall, AstraZeneca, Bial, Bristol‐Myers Squibb, Eli Lilly, Forest Research Institute, Geodon Richter, Glaxo‐Smith‐Kline, Janssen‐Cilag, Jazz, Johnson & Johnson, Lundbeck, Merck and Co. Inc., Novartis, Organon, Otsuka, Pfizer Inc, Sanofi‐Aventis, Servier, Shering‐Plough, Takeda, United Biosource Corporation, and Wyeth. Dr. Martinez‐Aran has received research funding from the Spanish Ministry of Innovation. Dr Rafael Tabarés‐Seisdedos has received grants from Lilly, Pfizer, and Astra‐Zeneca Companies.
The rest of coauthors have no conflict of interest.
References
-
- World Health Organization. The global burden of disease: 2004 update.WHO Press; 2008.
-
- Martinez‐Aran A, Vieta E, Colom F, et al Cognitive impairment in euthymic bipolar patients: Implications for clinical and functional outcome. Bipolar Disord 2004;6:224–232. - PubMed
-
- Zubieta JK, Huguelet P, O’Neil RL, Giordani BJ. Cognitive function in euthymic bipolar I disorder. Psychiatry Res 2001;102:9–20. - PubMed
-
- Mur M, Portella MJ, Martinez‐Aran A, Pifarre J, Vieta E. Persistent neuropsychological deficit in euthymic bipolar patients: Executive function as a core deficit. J Clin Psychiatry 2007;68:1078–1086. - PubMed
